Investment Rating - The report maintains a "Recommended" rating, emphasizing the importance of defensive stability and timely investment opportunities in the transportation sector [1]. Core Insights - The transportation sector's performance in November 2025 was generally average, outperforming the CSI 300 index, with highways leading the performance among sub-sectors [4][10]. - The report highlights a low interest rate environment, with the 10-year government bond yield at 1.82% as of November 21, 2025, indicating a stable financial backdrop for investments [20]. - The report identifies high dividend yield opportunities in both A-shares and H-shares within the transportation sector, with specific recommendations for companies like Sichuan Chengyu and Anhui Wantong Highway [68][70]. Monthly Market Performance - The transportation sector saw a cumulative decline of 2.24% from November 1 to November 21, 2025, outperforming the CSI 300 index by 1.79 percentage points [9]. - The sub-sectors of highways, railways, and ports had cumulative declines of -2.11%, -2.47%, and -2.97% respectively during the same period, but all outperformed the CSI 300 index [10]. - Year-to-date performance showed highways down 11.11%, railways down 15.77%, and ports down 4.83%, indicating a challenging year overall [10]. Highway Sector Tracking - In September 2025, highway passenger traffic was 934 million, down 4.3% year-on-year, while freight traffic increased by 5.2% to 3.891 billion tons [28]. - The report notes that the highway sector is expected to see stable performance improvements in 2026, driven by policy optimizations and local state-owned enterprise actions [68]. Railway Sector Tracking - In October 2025, railway passenger volume reached 410 million, up 10.1% year-on-year, while freight volume was 4.58 million tons, a slight increase of 0.6% [40][43]. - The report emphasizes the potential for investment opportunities in the railway sector, particularly in high-quality assets like the Beijing-Shanghai High-Speed Railway [70]. Port Sector Tracking - The report indicates that port cargo throughput for the four weeks ending November 16, 2025, was 1.057 billion tons, reflecting a year-on-year growth of 4.6% [48]. - The report highlights the importance of long-term value in port assets, suggesting that leading ports are undervalued in terms of their earnings stability and potential for dividend growth [71][72].

Group 1: Policy Insights - The speech by the General Secretary on November 21 emphasized the importance of reform and innovation, stating that rural reform should learn from past mistakes and promote openness[1] - The focus on maintaining reasonable investment growth and improving investment efficiency was highlighted during recent inspections in Shandong and Hebei[2] - The State-owned Assets Supervision and Administration Commission (SASAC) held a meeting on November 21, resulting in the signing of key projects involving 17 units in critical sectors such as new materials and artificial intelligence[12] Group 2: Economic Development Strategies - The need for a comprehensive legal and policy framework to guide outward-oriented enterprises was stressed during inspections in Hubei and Hunan[2] - The importance of enhancing traditional industries and nurturing emerging sectors was reiterated, with a focus on optimizing government investment[9] - The launch of commercial trials for satellite IoT services was announced at the 2025 China 5G+ Industrial Internet Conference, indicating a push towards advanced technology integration[13]

Investment Strategy - The oil and gas capital expenditure trend is declining, leading to a slowdown in supply growth. Since the signing of the Paris Agreement in 2015, global capital expenditure in the oil and gas upstream sector has significantly decreased, with a notable drop of nearly 22% from the 2014 peak to $351 billion in 2021. This trend is expected to continue as major energy companies face pressure to decarbonize and shift focus towards energy transition and renewable projects [9][25][27] - The current active drilling rig count in the US remains low, with new well costs closely aligned with current oil prices, limiting profit margins. The growth rate of US oil production is anticipated to slow down, with evidence emerging from the first half of 2025 [9][25][27] Oil Market - Brent crude oil spot price is currently at $63.54 per barrel, reflecting a week-on-week increase of 0.63%, while WTI crude oil is at $59.43 per barrel, down 0.43% [10][28] - The geopolitical situation, particularly the easing of tensions in the Russia-Ukraine conflict, is contributing to a volatile oil price environment. The expectation of a breakthrough in diplomatic negotiations has led to fluctuations in oil prices [10][28] Coal Market - The average market price for Qinhuangdao port thermal coal (Q5500) is reported at 820 RMB per ton, with a week-on-week increase of 0.35%. However, the market is experiencing a stalemate as downstream demand remains cautious towards high prices [11][12] - The total inventory at nine ports in the Bohai Rim is reported at 23.93 million tons, up 6.74% week-on-week, while southern ports report a decrease of 1.48% to 603.8 million tons [11][12] Coking Coal Market - Coking coal prices are experiencing a high-level consolidation, with the price of coking coal at the Jingtang port reported at 1,780 RMB per ton, down 4.30% week-on-week. The price of coking coal is less regulated compared to thermal coal, allowing producers to benefit from price increases [13][14] - The average daily iron output from 247 steel mills is reported at 2.3621 million tons, reflecting a slight decrease of 0.30% week-on-week, indicating a weak demand environment for steel products [13][14] Natural Gas Market - Russian LNG is entering the Chinese market at prices 20-30% lower than market rates, despite US pressure on Japan and Europe to halt imports of Russian LNG. This influx is contributing to a stable supply environment [14][15] - The average price of natural gas in the US is reported at $4.44 per million British thermal units, down 1.4% week-on-week, while European gas prices are on the rise [14][15] Oilfield Services - The oilfield services sector is expected to maintain its growth due to government policies aimed at ensuring energy security. The capital expenditure of major oil companies is projected to remain high, supporting the oilfield services industry's outlook [16][17] - The global active rig count is reported at 1,800, with a slight decrease in the Middle East and Asia-Pacific regions, while the US shows a week-on-week increase of 5 rigs [16][17]

Investment Rating - The report maintains a "Recommended" rating for Pinduoduo (PDD) with a target price of $139.04 [2][9] Core Insights - Pinduoduo's Q3 2025 revenue reached 108.28 billion yuan, a year-on-year increase of 9%. Operating profit was 25.03 billion yuan, up 3% year-on-year, while Non-GAAP operating profit was 27.08 billion yuan, reflecting a 1% increase. Non-GAAP net profit attributable to ordinary shareholders was 31.38 billion yuan, a 14% year-on-year growth [2][9] - The company is focusing on long-term quality growth, with a commitment to enhance platform investments and support merchants through initiatives like the "100 Billion Support Plan" [9][10] - Despite a slowdown in advertising revenue growth, transaction service revenue showed steady growth, with Q3 2025 online market service and other income at 53.35 billion yuan, up 8% year-on-year, and transaction service revenue at 54.93 billion yuan, up 10% year-on-year [9][10] Financial Summary - Total revenue projections for Pinduoduo from 2025 to 2027 are 430.67 billion yuan, 495.50 billion yuan, and 557.63 billion yuan respectively, with corresponding Non-GAAP net profits of 114.90 billion yuan, 139.90 billion yuan, and 165.20 billion yuan [4][10] - The company’s earnings per share (EPS) are projected to be 18.67 yuan in 2025, 22.85 yuan in 2026, and 27.32 yuan in 2027, with a price-to-earnings (P/E) ratio of 10.8 in 2025, decreasing to 7.4 by 2027 [4][10] - The total market capitalization of Pinduoduo is approximately 1,139.39 billion yuan, with a debt-to-asset ratio of 36.23% and a book value per share of 68.93 yuan [6][10]

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 25 yuan [2][8]. Core Insights - The company is gradually overcoming the impact of centralized procurement, with business expansion accelerating. The revenue for the first three quarters of 2025 was 258 million yuan, a decrease of 19.73% year-on-year, while the net profit attributable to shareholders was 6 million yuan, down 76.33% [2][8]. - In Q3 2025, the revenue was 99 million yuan, a decline of 6.36% year-on-year, indicating a significant improvement compared to the first half of the year [2][8]. - The company has completed the integration of its subsidiary, Hebei Toukeng, and is entering the invasive fungal disease detection field, which fills a gap in its product offerings [8]. Financial Performance Summary - The total revenue forecast for 2024A is 437 million yuan, with a year-on-year growth rate of -19.5%. For 2025E, the revenue is expected to be 383 million yuan, with a growth rate of -12.4%. By 2026E, the revenue is projected to increase to 469 million yuan, reflecting a growth rate of 22.4% [4][9]. - The net profit attributable to shareholders is forecasted to be 34 million yuan in 2024A, dropping to 9 million yuan in 2025E, and then rising to 41 million yuan in 2026E, with a significant growth rate of 371.7% [4][9]. - The company maintains a high R&D expense ratio, with 15.52% for the first three quarters of 2025 and 17.16% for Q3 2025, indicating a commitment to innovation and product development [8]. Business Expansion and Product Development - The company is actively pursuing mergers and acquisitions to enhance its competitive edge in the tumor diagnosis field, including the acquisition of Kanglu Bio, a leader in the pathology diagnosis segment [8]. - New product lines in autoimmune, metabolic, hormone, and lung cancer methylation testing are contributing to revenue growth, alongside the integration of external acquisitions [8]. - The company has received medical device registration certificates for several new reagents, enhancing its product pipeline and market offerings [8].

Investment Rating - The report maintains a "Recommend" rating for the company with a target price of 6.10 yuan [2][10]. Core Insights - The company reported a revenue of 4.703 billion yuan for the first three quarters of 2025, a year-on-year decrease of 8.43%. The net profit attributable to shareholders was -20.09 million yuan, down 84.08% year-on-year [2]. - In Q3 2025, the company achieved a revenue of 1.483 billion yuan, a decline of 10.93% year-on-year, with a net profit of -26.87 million yuan, representing a 183.10% decrease year-on-year [2]. - The gross margin improved to 24.33%, an increase of 1.29 percentage points year-on-year, indicating a positive trend despite the overall decline in profitability [10]. - The operating cash flow for the first three quarters was -824 million yuan, an improvement of 46.03% year-on-year, reflecting enhanced operational quality [10]. - The company is expected to see a gradual recovery in net profit from 44 million yuan in 2024 to 308 million yuan in 2027, with a projected net profit growth rate of 113.1% in 2025 [4][10]. Financial Summary - Total revenue is projected to decline from 6.829 billion yuan in 2024 to 6.107 billion yuan in 2027, with a compound annual growth rate of -3.5% [4]. - The net profit is expected to increase significantly from 44 million yuan in 2024 to 308 million yuan in 2027, with a growth rate of 171.5% in 2025 [4]. - The earnings per share (EPS) is forecasted to rise from 0.04 yuan in 2024 to 0.28 yuan in 2027 [4]. - The price-to-earnings (P/E) ratio is projected to decrease from 131 times in 2024 to 19 times in 2027, indicating a more attractive valuation over time [4].

Group 1: Credit Strategy and Market Overview - The credit bond market has experienced narrow fluctuations in yields, with a divergence in credit spreads. The market is currently influenced by geopolitical tensions and a pullback in US equities, leading to a weakened risk appetite for equities, while the bond market lacks a clear trading direction [1][8] - The excess spread of credit bond ETFs has risen significantly, indicating a rebound after a period of decline. This is attributed to the overall weak performance of credit bonds and the good liquidity of constituent bonds, which have seen a significant drop in valuation [1][9] - The current period is seen as a good window for accumulating interest-bearing assets, with the yield spread for 3-year bonds compressed below the lowest point expected for 2024, suggesting a low cost-performance ratio [1][12] Group 2: Long-term Credit Opportunities - There is a notable increase in the allocation of long-term credit bonds (10 years and above) by insurance and other products, indicating a trend towards extending duration for yield enhancement. Funds have shown a net buying trend for bonds with maturities of 5-7 years while slightly selling off 7-10 year bonds [2][21] - The yield for long-term credit bonds rated AA+ and above is currently in the range of 2.14%-2.66%, with credit spreads between 22-60 basis points, indicating sufficient spread protection [2][21] Group 3: Key Policies and Events - Jilin Province has met the conditions to exit the list of high-risk debt provinces, which is expected to open up new financing opportunities for regional development and bond issuance [3][27] - The support from Shenzhen Metro Group for Vanke's healthy development is crucial as Vanke faces significant operational challenges and debt repayment pressures [3][27] - CICC plans to merge with Dongxing Securities and Xinda Securities, which is expected to enhance market recognition and resource integration following regulatory support for brokerage mergers [3][27]

Investment Rating - The report indicates a positive investment outlook for the innovative drug sector, particularly focusing on RNA-targeted therapies for metabolic diseases [5][6]. Core Insights - The approval of the first APOC3 siRNA therapy for treating Familial Chylomicronemia Syndrome (FCS) marks a significant milestone in the RNA-targeted therapy landscape, showcasing the potential of these therapies in managing lipid disorders [17][28]. - RNA-targeted therapies, including small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), are being developed to effectively lower triglyceride levels and improve patient compliance due to reduced dosing frequency [5][10]. - The report highlights ongoing clinical trials and the promising results of therapies like volanesorsen and olezarsen, which have shown significant reductions in triglyceride levels and lower incidence of acute pancreatitis in patients with FCS [17][28][34]. Summary by Sections Section 1: Focus on Innovative Drugs - The report emphasizes the rapid advancements in RNA-targeted therapies for metabolic diseases, particularly in the context of lipid management [5][6]. - Key developments include the approval of siRNA therapies that target APOC3 mRNA, which is crucial for regulating triglyceride levels in patients with FCS [10][17]. Section 2: Clinical Developments - The report details various therapies in clinical stages, including volanesorsen and olezarsen, which have received FDA approval and demonstrated efficacy in lowering triglyceride levels significantly [17][28]. - Clinical trial results indicate that patients treated with these therapies experienced substantial reductions in triglyceride levels compared to placebo groups, with olezarsen showing a 43.5% reduction at six months [28][34]. Section 3: Market Dynamics - The report outlines the competitive landscape, noting that several companies are advancing their RNA-targeted therapies through clinical trials, with a focus on improving patient outcomes and safety profiles [33][34]. - The potential market for these therapies is substantial, given the prevalence of metabolic diseases and the need for effective treatment options [5][6].

Investment Strategy - The report emphasizes that Xinjiang is benefiting from two major strategic shifts: moving from coastal economies to the Belt and Road Initiative, positioning Xinjiang as a frontier hub with geographical advantages. This shift is expected to enhance energy security and promote coal chemical industry development [7][8] - The report highlights the importance of coal chemical investment and state-owned enterprise reform as two main investment themes in Xinjiang. The external environment for coal chemical development is now favorable, with rising coal prices and a focus on resource allocation towards the western regions of China [7][8] Xinjiang Index Situation - The Xinjiang index is reported at 121.12, down 7.68% week-on-week. The Xinjiang coal chemical investment index is at 119.79, also down 7.67%, while the state-owned enterprise reform index stands at 123.83, down 7.08% [14] - The report lists the top gainers and losers in the market, with Guotong Co., Ltd. (002205.SZ) gaining 10.38% and Huijia Times (603101.SH) losing 15.07% [14] Key Data Tracking - Key prices in Xinjiang include Q5000 mixed coal at 100 CNY/ton, Q5200 mixed coal at 215 CNY/ton, and main coking coal at 700 CNY/ton. The price of methanol is reported at 1530 CNY/ton, with a price difference of -482.5 CNY/ton compared to East China [20] - In October 2025, the coal railway dispatch volume from state-owned key coal mines was 3.429 million tons, a year-on-year decrease of 4.14%, while the raw coal production in Xinjiang was 44.816 million tons, down 5.00% year-on-year [20] Key News and Company Announcements - Guanghui Logistics has signed new transportation agreements for 2026, with external customer orders exceeding 7 million tons, expected to generate a total contract value of approximately 700 million CNY. This positions the company to further solidify its market position [34] - The report mentions several ongoing coal chemical projects in Xinjiang, including a 1.2 million ton coal-to-LNG project and an 800,000 ton coal-to-olefins project, with significant investments aimed at enhancing local resource utilization [34][38] Overview of Target Companies - The report suggests focusing on companies involved in coal chemical projects in Xinjiang, including TBEA, Jiufeng Energy, Baofeng Energy, Guanghui Energy, and Hubei Yihua. Additionally, companies providing services to coal chemical projects and local state-owned enterprises are highlighted as potential investment opportunities [11][13]

债券研究 证 券 研 究 报 告 【债券周报】 存单周报（1117-1123）：月末关注银行负债 边际变化 债券周报 2025 年 11 月 23 日 华创证券研究所 证券分析师：周冠南 电话：010-66500886 邮箱：zhouguannan@hcyjs.com 执业编号：S0360517090002 证券分析师：宋琦 电话：010-63214665 邮箱：songqi@hcyjs.com 执业编号：S0360523080002 相关研究报告 《【华创固收】政策双周报（0530-0612）：买断 式逆回购前置操作，中美经贸磋商原则上达成框 架 》 2025-06-12 《【华创固收】评级披露仍较缓慢，关注权益轮 动向转债传导——可转债周报 20250609》 2025-06-09 《【华创固收】央行开始买债了吗？——债券周 报 20250608》 2025-06-08 《【华创固收】存单周报（0602-0608）：资金预 期有所缓和，关注存单配置价值》 2025-06-08 《【华创固收】关注震荡市场利差被动走阔的加 仓机会——信用周报 20250607》 2025-06-07 证监会审核华创证券投资咨 ...